Plus   Neg

HMS Holdings Lowers FY19 Revenue Guidance - Quick Facts

HMS Holdings Corp. (HMSY) announced, for fiscal 2019, the company now expects adjusted EBITDA in a range of $182 - $187 million, revised from prior guidance range of $185 - $190 million. For fiscal 2019, HMS Holdings now projects total revenue in a range of $630 - $640 million, updated from prior outlook range of $650 - $660 million. Analysts polled by Thomson Reuters expect the company to report revenue of $655.54 million, for the quarter. Analysts' estimates typically exclude special items.

Third-quarter adjusted EPS was $0.30, which included a net benefit of $0.06 per share related to a gain on investment, compared to adjusted EPS of $0.31, a year ago. Excluding the gain on investment, adjusted EPS in the third quarter of 2019 was $0.24. On average, 14 analysts polled by Thomson Reuters expected the company to report profit per share of $0.28, for the quarter.

Total revenue in the third quarter was $146.8 million, compared to $154.2 million, prior year. Analysts expected revenue of $165.8 million, for the quarter.

The company's Board has authorized the repurchase of up to $50 million of common stock, on a discretionary basis, for a period of up to two years. The new authorization replaces a program that expires in November 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
Follow RTT